# A Phase II Clinical Study of Epigallocatechin-3-gallate in Patients With Esophageal Squamous Cancer

> **NCT06398405** · PHASE2 · RECRUITING · sponsor: **Shandong Cancer Hospital and Institute** · enrollment: 72 (estimated)

## Conditions studied

- Esophageal Cancer
- Dysphagia, Esophageal
- Epigallocatechin Gallate

## Interventions

- **OTHER:** Epigallocatechin-3-gallate

## Key facts

- **NCT ID:** NCT06398405
- **Lead sponsor:** Shandong Cancer Hospital and Institute
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-04-22
- **Primary completion:** 2026-04-22
- **Final completion:** 2026-05-22
- **Target enrollment:** 72 (ESTIMATED)
- **Last updated:** 2024-05-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06398405

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06398405, "A Phase II Clinical Study of Epigallocatechin-3-gallate in Patients With Esophageal Squamous Cancer". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT06398405. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*